Last 2,360 GBp
Change Today +2.00 / 0.08%
Volume 185.8K
HIK On Other Exchanges
As of 11:35 AM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

hikma pharmaceuticals plc (HIK) Snapshot

2,372 GBp
Previous Close
2,358 GBp
Day High
2,382 GBp
Day Low
2,350 GBp
52 Week High
01/13/15 - 2,500 GBp
52 Week Low
02/5/14 - 1,187 GBp
Market Cap
Average Volume 10 Days
1.56 GBp
Shares Outstanding
0.20 GBp
Dividend Yield

Related News

No related news articles were found.

hikma pharmaceuticals plc (HIK) Related Businessweek News

View More BusinessWeek News

hikma pharmaceuticals plc (HIK) Details

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms in the Middle East and North Africa, the United States, and Europe. It operates through three segments: Branded, Injectable, and Generic. The Branded segment offers 499 products in 1,256 dosage strengths and forms, which lie in the anti-infective, cardiovascular, central nervous system (CNS), and diabetes therapeutic areas. The Injectables segment markets 200 branded and non-branded products in 379 dosage strengths and forms with a focus on CNS, anti-infective, musculoskeletal, cardiovascular, and oncological therapeutic areas. This segment also offers sterile liquid, powder, lyophilized, and cytotoxic products. The Generics segment provides 11 products in 44 dosage strengths and forms for various therapeutic areas including analgesic, anti-infective, anti-inflammatory, cardiovascular, CNS, respiratory, hormonal, and others. This segment markets its products to chain stores, wholesalers, distributors, health systems, and governmental agencies in the form of tablets, capsules, solutions, and suspensions. In addition, the company offers anesthetics, anti-histamines, gastroenterology and metabolism, dermatology, genitourinary system, transplantation, vitamins and supplements, and miscellaneous products. Further, it manufactures plastic specialized medicinal sterile containers and API; and conducts bio-equivalency studies. The company was founded in 1978 and is based in London, the United Kingdom.

7,067 Employees
Last Reported Date: 03/11/14
Founded in 1978

hikma pharmaceuticals plc (HIK) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $2.4M
Executive Vice Chairman, Chief Executive Offi...
Total Annual Compensation: $1.6M
Compensation as of Fiscal Year 2013.

hikma pharmaceuticals plc (HIK) Key Developments

Takeda Pharmaceutical Company Limited Updates Regarding Colcrys Litigation Against Hikma Pharmaceuticals and U.S. Food and Drug Administration

Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals U.S.A. Inc. stated that TPUSA will continue its patent infringement litigation against Hikma Pharmaceuticals and its lawsuit against the U.S. Food and Drug Administration despite two recent court rulings that allowed Hikma to launch its colchicine product. On January 9, 2015, the United States Court of Appeals for the Federal Circuit upheld an earlier decision by the United States District Court for the District of Delaware that affirmed the denial of Takeda’s request for a preliminary injunction. The requested injunction would have prohibited the sale of Hikma’s colchicine product during the pendency of Takeda’s patent infringement litigation against Hikma. Colcrys ® (colchicine, USP) is sold by TPUSA and is protected by patents that extend through 2028 and 2029. A trial date in the patent case has not been set. Also on January 9, 2015, the United States District Court for the District of Columbia denied Takeda’s request to overturn the FDA approval of Hikma’s product. Takeda intends to appeal.

Hikma Pharmaceuticals to Launch Colchicine 0.6mg Capsules

Hikma Pharmaceuticals PLC pharmaceutical group announced that Takeda Pharmaceuticals U.S.A. Inc. has been unsuccessful in appealing the decision by the United States District Court for the District of Delaware to deny Takedas motion for a preliminary injunction in relation to the distribution of Hikmas colchicine 0.6mg capsules for the prophylaxis of gout flares in adults. The injunction, which was granted to Takeda on 9 October 2014, has been vacated. Hikma will now prepare to distribute its colchicine, which it will market under the brand name MITIGARE(TM). Hikma will also be preparing to launch an authorised generic of MITIGARE(TM), increasing patient access to this important product.

Hikma Pharmaceuticals plc Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 03:00 PM

Hikma Pharmaceuticals plc Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 03:00 PM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Mazen Samih Taleb Darwazeh, Executive Vice Chairman, Chief Executive Officer of MENA & Emerging Markets, President of MENA & Emerging Markets, Member of Nomination Committee and Member of Compliance, Responsibility & Ethics Committee.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HIK:LN 2,360.00 GBp +2.00

HIK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $42.40 USD -0.81
BTG PLC 791.00 GBp -3.50
Richter Gedeon Nyrt 3,740 -35.00
Impax Laboratories Inc $36.60 USD -1.09
STADA Arzneimittel AG €27.42 EUR +0.184
View Industry Companies

Industry Analysis


Industry Average

Valuation HIK Industry Range
Price/Earnings 23.0x
Price/Sales 4.8x
Price/Book 6.1x
Price/Cash Flow 22.9x
TEV/Sales 4.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HIKMA PHARMACEUTICALS PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at